The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer.
[PURPOSE] Cancer cachexia leads to poor outcomes, especially for patients with advanced stage disease.
- p-value p < 0.001
- p-value p = 0.002
APA
Sakamoto T, Kishino M, et al. (2024). The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer.. Surgery today, 54(12), 1498-1504. https://doi.org/10.1007/s00595-024-02877-z
MLA
Sakamoto T, et al.. "The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer.." Surgery today, vol. 54, no. 12, 2024, pp. 1498-1504.
PMID
38822841
Abstract
[PURPOSE] Cancer cachexia leads to poor outcomes, especially for patients with advanced stage disease. The cachexia index (CXI), a novel biomarker for cancer cachexia, has been identified as a prognostic indicator for several malignancies. The present study aimed to clarify the prognostic significance of the CXI for patients with recurrent pancreatic cancer.
[METHODS] This retrospective study enrolled 113 patients diagnosed with recurrence following pancreatectomy for pancreatic cancer, to analyze the association between the CXI and prognostic survival.
[RESULTS] The 2-year overall survival rate and median survival of all patients were 28.5% and 12.6 months, respectively. The 2-year overall survival curve in the high CXI group was significantly better than that in the low CXI group (p < 0.001). The rate of chemotherapy after recurrence was significantly lower in the low CXI group than in the high CXI group (p = 0.002). Multivariate analysis identified the CXI as an independent prognostic factor for patients with recurrent pancreatic cancer (p = 0.011).
[CONCLUSIONS] The CXI proved useful for predicting the post-recurrence prognosis of patients with recurrent pancreatic cancer. Patients with a low CXI at the time of recurrence have poorer prognostic outcomes than those with a high CXI.
[METHODS] This retrospective study enrolled 113 patients diagnosed with recurrence following pancreatectomy for pancreatic cancer, to analyze the association between the CXI and prognostic survival.
[RESULTS] The 2-year overall survival rate and median survival of all patients were 28.5% and 12.6 months, respectively. The 2-year overall survival curve in the high CXI group was significantly better than that in the low CXI group (p < 0.001). The rate of chemotherapy after recurrence was significantly lower in the low CXI group than in the high CXI group (p = 0.002). Multivariate analysis identified the CXI as an independent prognostic factor for patients with recurrent pancreatic cancer (p = 0.011).
[CONCLUSIONS] The CXI proved useful for predicting the post-recurrence prognosis of patients with recurrent pancreatic cancer. Patients with a low CXI at the time of recurrence have poorer prognostic outcomes than those with a high CXI.
MeSH Terms
Humans; Pancreatic Neoplasms; Cachexia; Male; Female; Prognosis; Aged; Retrospective Studies; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Pancreatectomy; Aged, 80 and over; Adult
같은 제1저자의 인용 많은 논문 (3)
- Advancements and limitations of image-enhanced endoscopy in colorectal lesion diagnosis and treatment selection: A narrative review.
- The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence prognosis in patients with pancreatic cancer: a retrospective study.
- Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer.